<DOC>
	<DOCNO>NCT01794845</DOCNO>
	<brief_summary>Whether low-dose radiation addition Taxotere Erbitux improve response rate patient recurrent unresectable head neck squamous cell carcinoma .</brief_summary>
	<brief_title>Phase II Trial Using Erbitux+ Taxotere With Low Dose Fractionated Radiation Recurrent Unresectable Locally Advanced Head Neck Carcinoma</brief_title>
	<detailed_description>The investigator 's approach base following reason : - Low dose hyper-radiation sensitivity response significantly enhance Taxotere- induce G2/M cell cycle arrest . - LDFRT render enhance bax activation mediate mode cell death . - Erbitux arrest cell G1/G0 phase lead p21-mediated mode cell death . - The toxicity profile expect minimal . Based mentioned reason , propose novel schema treatment recurrent SCCHN .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Patients must pathologically confirm recurrence ( reappearance previously clear ) squamous cell cancer primary upper aerodigestive tract .Patients may experience one recurrence long first recurrence occur ≥ 6 month follow end prior RT . The recurrence must define bi unidimensional measurement . Recurrence must confine head neck clavicle ( locoregional recurrence ) . The patient must candidate surgical resection . Patients must least 6 month completion prior chemotherapy radiation therapy . Patients may receive prior chemotherapy component primary treatment , recurrent disease . ECOG performance status 02 . Granulocytes &gt; = 1500/mm3 , platelet &gt; = 100,000/mm3 , serum bilirubin = &lt; 1.5 mg/dl , creatinine &lt; 1.5 mg/dl within 3 week prior registration . LFT 's ≤ 2 x normal ( SGOT/SGPT/Alkaline Phosphatase ) .If &gt; 2 x normal , liver ultrasound CT require exclude metastasis . If negative metastasis , patient eligible . Patients must sign studyspecific inform consent form prior study entry Distant metastases outside head neck . Primary disease nasopharynx salivary gland . Other concurrent invasive malignancy . Prior invasive malignancy unless disease free least two year ( except prior situ malignancy , e.g . cervix , breast , nonmelatomatous skin cancer , etc . permissible ) . Intercurrent medical illness would impair patient tolerance therapy limit survival . Preexisting grade ≥ 2 peripheral sensory neuropathy Pregnant nursing woman exclude potential teratogenic effect potential unknown effect nurse newborn .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>SCCHN</keyword>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Squamous Cell Carcinoma</keyword>
	<keyword>Recurrent</keyword>
</DOC>